ROS Therapeutics ApS: Financial statements 2021
CVR: 39507501
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
ROS Therapeutics ApS (CVR 39507501) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -4,763,306 and a net result of DKK -4,381,494 compared with DKK -1,900,359 the year before. Equity in the 2021 report amounted to DKK -758,038. The company had 1 employee in the financial year.
- Gross Profit
- DKK -4,763,306
- Profit/Loss
- DKK -4,381,494
- Equity
- DKK -758,038
- Total Assets
- DKK 6,287,418
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -4.8 mio. | -4.4 mio. | -758 t. | 1 |
| 2020 | - | -2 mio. | -1.9 mio. | 3.6 mio. | 1 |
| 2019 | - | -2.1 mio. | -1.9 mio. | 5 mio. | 0 |
Official annual report
Find more companies like ROS Therapeutics ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
ROS Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK -2,037,635, and the net result was DKK -1,900,359.
About ROS Therapeutics ApS
ROS Therapeutics ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2018. The company is in liquidation. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Hanne Damgaard Jensen. The company is owned by Sandlykke A/S, HDJ & LEJ Invest ApS and ROS Therapeutics Holding ApS. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK -543,530 and a net result of DKK -1,212,924 compared with DKK -1,314,915 the year before. Equity in the 2025 report amounted to DKK -7,954,408.